Horizon Scanning of Multiple Sclerosis Expenditure in Italy (2025-2029): Updated Insights from the Oracle Model. (PubMed, Neurol Ther) - Oct 4, 2026 - "Despite higher patient volumes and new launches, total DMT expenditure is expected to decline from €784 million in 2024 to €622 million in 2029, mainly driven by losses of exclusivity and price renegotiations. Results support the sustainability of the NHS and the reallocation of resources toward innovation, including innovative therapies for currently underserved populations such as NR-SPMS."
Journal • CNS Disorders • Multiple Sclerosis
|
|
; Alessandro Carrera; Andrea Marcellusi; Andrea Marinozzi; Diego Centonze; Eleonora Cocco; Francesca Donnaloja; Francesco Patti; Maria Vittoria Azzi; Massimiliano Calabrese; Roberta Di Turi
|